Abstract
Background Approximately 1.2 billion doses of novel type 2 oral polio vaccine (nOPV2) have been administered in response to circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks since 2021. Although infants are eligible to receive the vaccine from birth, the induction of intestinal mucosal immunity by nOPV2 in newborns has not been directly evaluated.
Methods In a randomized, placebo-controlled, phase 2 clinical trial in Bangladesh (2020–2021), 215 healthy newborns received two doses of either nOPV2 (n=110) or placebo (sucrose; n=105), at birth (0-3 days) and 4 weeks later. Intestinal mucosal immunity was assessed by measuring poliovirus type 2 (PV2)-specific neutralizing activity and immunoglobulin (Ig)A levels in stool collected biweekly from birth to 8-weeks.
Results Newborns vaccinated with two doses of nOPV2 had strong intestinal mucosal immune responses that differed significantly from the placebo group (p<0.0001 for PV2-specific neutralization from 2 weeks onward and p≤0.007 for PV2-specific IgA from 4 weeks onwards). Positive PV2-specific neutralization in stool (i.e., titers ≥16) was detected in 51.8% (57/110) of nOPV2-vaccinated newborns at 4 weeks and 90.0% (99/110) at 8 weeks (4 weeks after the second dose). Notably, PV2-specific antibody titers following the second dose were very similar for newborns who did and did not have first dose responses (p=0.67 for neutralization and p=0.38 for IgA at 8 weeks).
Conclusions Vaccination with two doses of nOPV2 in neonates induced high intestinal mucosal immune responses. In cVDPV2 outbreak settings, neonatal administration of nOPV2 may be a strategy to enhance population-level intestinal mucosal immunity.
Trial registration number NCT04693286
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04693286
Funding Statement
This work was supported by the Bill & Melinda Gates Foundation (grant number GC10058 to P. F. W.). The conclusions and opinions expressed in this work are those of the author(s) alone and shall not be attributed to the Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research and ethical review committees at the International Centre for Diarrhoeal Disease Research, Bangladesh provided ethical approval. Written informed consent was provided by all newborns parents/guardians before enrollment, including use of samples for further polio-related studies. Dartmouth-Hitchcock Institutional Review Board approved the de-identified samples analysis (#02002410).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
